Protocol Ledger

NCT03644667 · Phase II · COMPLETED

Tocilizumab in Cardiac Transplantation

Interventional Phase II clinical trial protocol NCT03644667 sponsored by National Institute of Allergy and Infectious Diseases (NIAID) in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-12-20 Enrollment: 385 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03644667
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)385 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03644667
Protocol FieldVerified Registry Value
NCT IdentifierNCT03644667
Consolidated Lead SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment385 participants (ACTUAL)
Registered Start Date2018-12-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI